Turning to the prescription trends. Quarter-over-quarter total prescriptions increased by approximately 36% to 19,823. Over the same period new prescriptions grew by approximately 28% to 9,658. Since these are IMS prescription numbers they do not reflect the 7.9% price increase we took in December of last year.In addition, we are seeing robust prescription growth early in our third fiscal quarter, which started April 1, 2012. Total prescriptions and new prescriptions for the first three weeks of April are up over 42% versus the same period in January. This strong star to the quarter further strengthens our belief in the long-term potential of NUEDEXTA for the treatment of pseudobulbar affect.
Avanir Pharmaceuticals' CEO Discusses F2Q2012 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts